Vyant Bio (VYNT) Reports In-Line Q3 EPS; Cash and Cash Equivalents of $23.2M

Vyant Bio (NASDAQ: VYNT) reported Q3 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.19 million.

For earnings history and earnings-related data on Vyant Bio (VYNT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c